China Kexing Stock Code

China Kexing is listed and traded on NASDAQ with the trading code of SVA.

China Kexing, the full name of Beijing Kexing Biological Products Co., Ltd., is a biological high-tech enterprise jointly funded by Kexing Holdings (Hong Kong) Co., Ltd. and Beijing Peking University Weiming Biological Engineering Group Co., Ltd. In order to develop China's high-tech biological engineering industry, it adopts advanced scientific and technological achievements at home and abroad, introduces international scientific management methods, researches, produces and sells vaccines for human use and related products, and provides technical consultation and technical services. So as to improve the prevention and treatment level of various major diseases at home and abroad, including hepatitis A and hepatitis B, and make contributions to human health.

Kexing Biopharmaceutical Co., Ltd. is an innovative biopharmaceutical enterprise, mainly engaged in the production and sales of R&D, recombinant protein drugs and microecological agents. Founded on August 22nd, 1997, its headquarters is located in Zhangqiu District, Jinan City, Shandong Province.

The company focuses on drug research and development in the fields of antivirus, tumor and immunity, hematology, digestion and degenerative diseases. , and successfully landed on the A-share Science and Technology Innovation Board in June 5438+February 65438+April 2020 with the stock code 688 136.

2002165438 February, Kexing Bio released the unaudited financial report for the first half of 20021. Its sales in the first half of 20265438 was +0, 1 billion, and its net profit was $5 1 billion.

202 1 12, China Kexing announced that the company had obtained two Omicrons from Hongkong. The latest laboratory research results show that one of Omicron virus strains is used to detect neutralizing antibodies in 20 sera inoculated with two doses of CoronaVac and 48 sera inoculated with three doses of CoronaVac. The positive rate of neutralizing antibody was 35%(7/20) in 20 sera inoculated with two doses of vaccine and 94% (45/20) in 48 sera inoculated with three doses of vaccine. The results showed that the third dose of vaccine could effectively improve the neutralization ability of serum to Omicron virus strain.

By the end of February, 20021and 65438+,comparative tests using another Omicron virus strain were in progress. China Kexing made further research on sera with different antibody levels at more post-immunization time points, so as to obtain a comprehensive evaluation of the impact of Omicrovirus strains on vaccines.